Figure 2
From: Biomarkers of axonal damage to favor early diagnosis in variant transthyretin amyloidosis (A-ATTRv)
(A) ROC curve analysis of NfL serum levels in A-ATTR-V30M patients vs. asymptomatic V30M-TTR variant carriers. (B) ROC curve analysis of NfL serum levels in A-ATTR-V30M patients vs. healthy controls.
